WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

VNRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.80%

Insider Buying (Last 12 Months): $304,711.62

Insider Selling (Last 12 Months): $18,000.00

VolitionRx Insider Trading History Chart

VolitionRx Share Price & Price History

^$0.68

▲ +0.0949 (16.33%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

VolitionRx Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Cameron John Reynolds	CEO	Buy	139,811	$0.57	$79,692.27	2,117,404
12/9/2024	Guy Archibald Innes	Director	Buy	174,764	$0.57	$99,615.48	617,085
12/9/2024	Jacob Vincent Micallef	Insider	Buy	43,691	$0.57	$24,903.87	394,352
8/20/2024	Guy Archibald Innes	Director	Buy	150,000	$0.67	$100,500.00	406,683
1/2/2024	Corp Ltd Eight	Major Shareholder	Sell	20,000	$0.90	$18,000.00	298,419
12/18/2023	Salvatore Thomas Butera	CEO	Buy	10,000	$0.83	$8,300.00	99,350
12/15/2023	Corp Ltd Eight	Major Shareholder	Sell	20,000	$0.75	$15,000.00	318,419
12/15/2023	Salvatore Thomas Butera	CEO	Buy	10,000	$0.77	$7,700.00	89,350
12/13/2023	Rodney Gerard Rootsaert	Insider	Buy	10,000	$0.60	$6,000.00	78,652
12/8/2023	Cameron John Reynolds	CEO	Buy	10,000	$0.67	$6,700.00	1,704,518
11/27/2023	Guy Archibald Innes	Director	Buy	20,000	$0.77	$15,400.00	627,161
11/24/2023	Guy Archibald Innes	Director	Buy	10,000	$0.76	$7,600.00	607,161
11/22/2023	Guy Archibald Innes	Director	Buy	20,000	$0.71	$14,200.00	597,161
11/16/2023	Salvatore Thomas Butera	CEO	Buy	10,000	$0.81	$8,100.00	79,350
9/5/2023	Phillip Barnes	Director	Buy	5,000	$1.30	$6,500.00	24,686
8/31/2023	Martin Charles Faulkes	Director	Buy	9,716	$1.28	$12,436.48	1,673,532
8/29/2023	Jacob Vincent Micallef	Insider	Buy	11,250	$1.24	$13,950.00	46,250
8/25/2023	Jacob Vincent Micallef	Insider	Buy	20,000	$1.24	$24,800.00	235,140
8/24/2023	Gaetan Michel	COO	Buy	5,000	$1.23	$6,150.00	212,997

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

SEC Filings (Institutional Ownership Changes) for VolitionRx (NYSE:VNRX)

8.09% of VolitionRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

VolitionRx Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	730,448	$0.44M	0.0%	+15.1%	0.788%
10/29/2024	Ground Swell Capital LLC	45,959	$28K	0.0%	+78.8%	0.050%
1/17/2024	Silverberg Bernstein Capital Management LLC	147,038	$0.11M	0.1%	N/A	0.187%
11/14/2023	Lagoda Investment Management L.P.	3,882,850	$2.68M	1.8%	-1.2%	4.969%

Data available starting January 2016

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Today's Range

Now: $0.68

$0.58

$0.68

50 Day Range

MA: $0.67

$0.55

$0.81

52 Week Range

Now: $0.68

$0.43

$1.23

Volume

419,173 shs

Average Volume

196,770 shs

Market Capitalization

$62.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Who are the company insiders with the largest holdings of VolitionRx?: VolitionRx's top insider investors include:
Cameron John Reynolds (CEO)
Martin Charles Faulkes (Director)
Guy Archibald Innes (Director)
Jacob Vincent Micallef (Insider)
Corp Ltd Eight (Major Shareholder)
Gaetan Michel (COO)
Salvatore Thomas Butera (CEO)
Rodney Gerard Rootsaert (Insider)
Phillip Barnes (Director)
Learn More about top insider investors at VolitionRx.
Who are the major institutional investors of VolitionRx?: VolitionRx's top institutional investors include:
Geode Capital Management LLC — 0.79%
Ground Swell Capital LLC — 0.05%
Learn More about top institutional investors of VolitionRx stock.
Which institutional investors are buying VolitionRx stock?: During the last quarter, VNRX stock was acquired by institutional investors including:
Geode Capital Management LLC
Ground Swell Capital LLC
Within the previous year, these company insiders have bought VolitionRx stock:
Cameron John Reynolds (CEO)
Martin Charles Faulkes (Director)
Guy Archibald Innes (Director)
Jacob Vincent Micallef (Insider)
Corp Ltd Eight (Major Shareholder)
Gaetan Michel (COO)
Salvatore Thomas Butera (CEO)
Rodney Gerard Rootsaert (Insider)
Learn More investors buying VolitionRx stock.